Quantcast

Latest Exelixis Stories

2014-04-09 16:23:19

LONDON, April 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Thyroid Cancer Global Clinical Trials Review, H2, 2013Thyroid Cancer Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Thyroid Cancer Global Clinical Trials Review, H2, 2013" provides data on the Thyroid Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Thyroid Cancer. It includes an overview...

2010-08-31 11:07:00

SAN FRANCISCO, Aug. 31 /PRNewswire/ -- Deloitte Recap recently presented the Allicense 2010 Breakthrough Alliance Award to pharmaceutical giant, Sanofi-aventis, and biotechnology firm, Exelixis, in recognition of their potential $1 billion alliance in which Exelixis gave Sanofi-aventis worldwide exclusive licenses for two early-stage cancer treatments and a stake in the development of PI3K inhibitor programs. In exchange, Sanofi-aventis provided Exelixis an upfront payment of $140 million...

2009-07-29 06:00:00

BRIDGEWATER, N.J., July 29 /PRNewswire-FirstCall/ -- Change Change Change at Change at on a constant on a constant Q2 reported exchange reported exchange 2009 basis rates H1 2009 basis rates ------- --------- -------- ------- -------...

2008-11-06 11:17:54

Exelixis, a development-stage biotechnology company, has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to discover novel therapies targeted against the liver X receptor, a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through January 12, 2009....

2008-11-06 06:00:21

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to discover novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. The collaboration, originally established in January of 2006 for a period of two years, was extended in 2007, at Bristol-Myers Squibb's request, through...

2008-10-23 09:00:38

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is being carried out in patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. In the trial, XL765 is orally...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related